Researcher
Alfons Verbruggen
- Disciplines:Medicinal products, Biomarker discovery and evaluation, Drug discovery and development, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Faculty of Pharmaceutical Sciences (Faculty)
Member
From1 Oct 2020 → Today - Radiopharmaceutical Research (Division)
Member
From1 Oct 1999 → 30 Sep 2019
Projects
1 - 10 of 10
- translational study of the modulation of fosfodiesterase type 10A expression by dopaminergic neurotransmission using molecular imagingFrom1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Oncocidia_the novel anticancer therapy: phase 0 clinical study.From1 Jan 2013 → 31 Dec 2013Funding: IOF - Industrial Research Fund
- Development and evaluation of PET ligands for the in vivo visualisation of phosphodiesterase type 5 (PDE5).From1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Synthesis and biological evaluation of carbon-11 and fluorine-18 labelled P2X7-receptor ligands for diagnosis of neurological diseases using positron emission tomographyFrom1 Oct 2011 → 30 Sep 2015Funding: FWO fellowships
- In vivo molecular imaging research (IMIR).From1 Nov 2010 → 31 Oct 2018Funding: BOF - Concerted Research Project from 1994
- Molecular and functional imaging as a pivotal tool for translational medicine in the field of neuroscience and oncology: a platform creating a bridge between basic research, clinical development and industrial application.From1 Oct 2010 → 30 Sep 2014Funding: IOF - Industrial Research Fund
- Preclinical validation and first in man study of PET radioligands for the cannabinoidreceptor type 2.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- Synthesis and (pre)clinical evaluation of PET radioligands for in vivo visualization of phosphodiesterase 10, an enzyme involved in neurological and psychiatric disorders.From1 Oct 2009 → 30 Sep 2010Funding: BOF - Other initiatives
- Development of a radiolabelled probes for the in vivo visualisation of the TRPV1 receptor with PETFrom1 Oct 2008 → 24 Jan 2013Funding: IWT personal funding - strategic basic research grants
- Anti-kanker therapie versterkt door kleine radioactief gelabelde compounds met affiniteit voor necrosis (sRALNAC): een Prrof-of-Principle experiment ter ondersteuning van een nieuw patent aanvraag.From1 Jul 2008 → 30 Jun 2009Funding: IOF - Industrial Research Fund
Publications
31 - 40 of 124
- In vivo visualization of PDE10A using positron emission tomography(2014)
Authors: Maarten Ooms, Guy Bormans, Alfons Verbruggen, Koen Van Laere
- Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A(2014)
Authors: Maarten Ooms, Sofie Celen, Michel Koole, Alfons Verbruggen, Koen Van Laere, Guy Bormans
Pages: 695 - 704 - Individualized dosimetry-based activity reduction of (90)Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy(2014)
Authors: Sofie Van Binnebeek, Kristof Baete, Michel Koole, Felix Mottaghy, Paul Clement, Luc Mortelmans, Karin Haustermans, Eric Van Cutsem, Alfons Verbruggen, Kris Bogaerts, et al.
Pages: 1141 - 1157 - Development of Radiolabeled PET Tracers for In Vivo Visualization of Phosphodiesterase Type 5 (PDE5)(2014)
Authors: Rufael Chekol, Guy Bormans, Alfons Verbruggen, Olivier Gheysens
Number of pages: 243 - Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic(2014)
Authors: Marlein Miranda Cona, Michel Koole, YUanbo Feng, Alfons Verbruggen, Raymond Oyen, Yicheng Ni
Pages: 819 - 829 - Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5)(2014)
Authors: Rufael Chekol, Olivier Gheysens, Peter Pokreisz, Stefan Janssens, Alfons Verbruggen, Guy Bormans
Pages: 155 - 162 - Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers(2014)
Authors: Ludwig Dubois, Sofie Celen, Alfons Verbruggen, Guy Bormans
Pages: 374 - 84 - PET Radioligands for in Vivo Visualization of Neuroinflammation(2014)
Authors: Dieter Ory, Sofie Celen, Alfons Verbruggen, Guy Bormans
Pages: 5897 - 913 - Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations(2014)
Authors: Marlein Miranda Cona, YUanbo Feng, Alfons Verbruggen, Peter de Witte, Raymond Oyen, Yicheng Ni
Pages: 852 - 61 - Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction(2014)
Authors: Marlein Miranda Cona, YUanbo Feng, Alfons Verbruggen, Raymond Oyen, Yicheng Ni
Pages: 427 - 435
Patents
1 - 4 of 4